Research and Innovation

Nuvance Health conducts groundbreaking research and innovation to improve patient care and advance the field of medicine.

At Nuvance Health®, research and innovation are a top priority—unlocking advancements that improve health care now and in the future.

Rudy L. Ruggles Biomedical Research Institute

Renowned scientists perform translational research, which uses scientific findings to improve the standard of patient care and advance our community’s health. Discover more about this groundbreaking work and expertise.

Rudy L. Ruggles Biomedical Research Institute
Research - African American Scientist

Clinical Trials

Nuvance Health serves as a research site for many national and international clinical trials. Learn how these studies evaluate new approaches to prevent, diagnose and treat disease.

View Open Trials
Researcher grabs test tube

Lyme Disease Research and Prevention

Researchers educate the public about Lyme disease prevention, developing new diagnostic methods and collaborating on biobanking efforts.

Lyme Disease Research and Prevention
test tubes with lyme disease label
test tubes icon
Biobanking

We collect and store a wide range of biological samples to serve as an ongoing resource for research. Our biobank supports clinical trials, improves the delivery of personalized medicine and enhances opportunities for collaboration and research funding.
light bulb icon
Clinical Outcomes and Health Services Research

We assess the health care delivery system and pull our findings into clinical practice. Learn about our research and how clinicians are shaping the future of patient care.
icon of person
Research Careers, Internships and Fellowships

We work to equip the next generation of clinicians and researchers with the skills they need to unlock major discoveries and improve patient care. Discover why Nuvance Health is an excellent place to start or continue a career in research.
icon of microscope
Cancer Research

Our translational cancer research focuses on new diagnostic and treatment options for gynecologic, pancreatic and thoracic cancers.

Research and Innovation at Nuvance Health

At Nuvance Health, research and innovation are a top priority—unlocking advancements that improve health care now and in the future. Highlights of the program include:

  • A full range of research initiatives:
    Offerings include translational, clinical and investigator-led research. This robust program is on par with that of major academic medical centers in our region and beyond.
  • Strong research pipeline:
    Sponsors and partner institutions seek out Nuvance Health based on our reputation for solid research. This broad network creates a strong pipeline of opportunities for eligible patients to participate in research.
  • Access to new treatments:
    We provide avenues for patients to be involved in important studies and trials close to home. Eligible patients may have access to promising new therapies before they’re widely available.
  • Career and educational opportunities:
    Nuvance Health offers a launchpad for a rewarding career. We also train the next generation of clinicians and researchers, through internships and fellowships, to make important discoveries.

Clinical Trial Listings

  • Alzheimer's 

    Evoke Plus
    A randomized double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus
    NIC/PTI-125
    76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease

  • Arrhythmia 

    APPRAISE
    Assessment of Primary Prevention Patients Receiving an Implanted Cardiac Defibrillator – Systematic Evaluation of ATP
    AZALEA-TIMI 71
    A multicenter, Randomized, Active-control study to evaluate the safety and tolerability of two blinded doses of Abenacimab compared with open label rivaroxaban in patients with Atrial Fibrillation
    Product Surveillance Registry Platform
    Evaluate the periodic reporting of safety and effectiveness of Medtronic market-released products for their intended use

  • Coronary Disease 

    ECLIPSE
    Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting Stents
    HP-4/TIMI 65/ORION 4
    A double-blind, randomized, placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease.
    Vesalius CV
    A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infactrion or Stroke

  • COVID-19 

    D8110C00001
    A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
    RESOLUTION
    A Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients with COVID-19

  • Crohn's Disease 
    GRAVITI
    A Randomized, Double-blind, Placebo-Controlled, Parellel-group, Multicenter study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Crohn's Disease
  • Eosinophilic Esophagitis 
    SP-1011-004 EAP
    APT-1011 (Fluticasone ODT) Expanded Access Protocol for Patients with Eosinophilic Esophagitis
    FLUTE III
    Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Randomized, Double-blind, Placebo-Controlled 24-Week Induction Study of APT-1011, followed by a Single-arm Open-label Extension, in Adult Subjects with Eosinophilic Esophagitis 
  • Heart Failure  

    DAPA ACT HF/TIMI 68

    This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients with heart failure with reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤40%) who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure
    EMPOWER (FKA CARILLON)
    The objective of this prospective, randomized, blinded clinical trial is to assess the safety and efficacy of the Carillon Mitral Contour System in treating heart failure with functional regurgitation (FMR).
    MIRACLE
    A Phase 2b, Randomised, Double-Blind, Active-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients with Heart Failure and Chronic Kidney Disease

  • Infectious Disease
    TPOXX-EAP
    Expanded Access IND Protocol: Use of Tecovirimat (TPOXX®) for Treatment of Human Non-Variola Orthopoxvirus Infections in Adults and Children
  • Lupus 

    Sable
    A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated with or without Benlysta (belimumab)
    Enlight-LN
    A Prospective Observational Registry of Patients Treated with LUPKYNIS (voclosporin) in the US

  • Migraine 

    AMG 334 Erenumab

    Phase 4 Open Label study to evaluate treatment satisfaction with Erenumab in patients with Migraine

  • Multiple Sclerosis 

    VERISMO
    An Observational Study of Ocrelizumab-Treated Patients with Multiple Sclerosis to Determine the Incidence and Mortality Rates of Breast Cancer and All Malignancies
    ESTEEM
    A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)

  • Parkinson's Disease 

    Orchestra

    A Double-Blind, Placebo-controlled, Randomized, 18-month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 In Study Participants with Early Parkinson's Disease

  • Pulmonary 

    CHRONICLE
    A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States.
    ASPEN
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis
    Harmony/ HBS-101-CL-010
    A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients with Idiopathic Hypersomnia
    Harmony/ HBS-101-CL-011
    An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients with Idiopathic Hypersomnia who Completed Study HBS-101-CL-010

  • Stroke 

    Aspire
    Anticoagulation in ICH Survivors for Stroke Prevention and Recovery (ASPIRE)

  • Surgery 
    TU100P2T4
    Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery after Surgery (ERAS) Protocol in Subjects Undergoing Bowel Resection
  • Vascular 

    STRIDE
    A Study of Patients with Lower Extremity Acute Limb Ischemia to Remove Thrombus with the Indigo® Aspiration System